12 results on '"Gabrielli, Sofianne"'
Search Results
2. Bridging knowledge gaps in paediatric chronic urticaria through a video-based educational tool.
- Author
-
Karim J, Gabrielli S, Mule P, Torabi B, Byrne A, De Schryver S, Gadoury-Lévesque V, Alizadehfar R, McCusker C, Zhang X, and Ben-Shoshan M
- Subjects
- Male, Female, Humans, Child, Infant, Child, Preschool, Adolescent, Ambulatory Care Facilities, Chronic Urticaria, Urticaria therapy
- Abstract
Background: There is a lack of patient educational resources about chronic urticaria (CU)., Aims: To develop and test the effectiveness of an education tool to help paediatric patients and their families better understand CU and its management., Methods: From July 2020 to May 2022, paediatric patients with a history of CU who presented to the allergy outpatient clinics at our institution were recruited. Consenting families and patients were asked to complete five questions related to the definition, causes and management of CU at the time of presentation to the clinic. Participants were shown a 5-min animated video addressing the main knowledge gaps about CU. At the end of the video, participants were redirected to the same five questions to respond again. The scores were recorded as a proportion of correct answers (range 0·0-1·0)., Results: In total, 53 patients [30 girls (56·6%), 23 boys (43·4%); mean age 9·7 ± 5·1 years, range 1·4-18·5 years] were recruited. The mean baseline pre-video education questionnaire score was 0·67 ± 0·2 (range 0·2-1·0), while the mean post-video score was 0·94 ± 0·1 (range 0·4-1·0), a mean score difference of 0·27, which was statistically significant (P < 0·001). At the 1-year follow-up, 14 (26·4%) patients answered the questionnaire again to assess retention of knowledge; the mean score was 0·83 ± 0·2 (range 0·2-1·0)., Conclusions: Our educational video was successful in educating patients and their families to better understand urticaria. Future studies should aim to optimize patient education through nontraditional tools such as videos, and compare knowledge gain using different methods of education., Competing Interests: Conflict of interest The authors declare that they have no conflict of interest., (© The Author(s) 2022. Published by Oxford University Press on behalf of British Association of Dermatologists. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.)
- Published
- 2023
- Full Text
- View/download PDF
3. Validation of the Urticaria Control Test (UCT) in Children With Chronic Urticaria.
- Author
-
Prosty C, Gabrielli S, Mule P, Noorah N, Baum S, Greenberger S, Ensina LF, Zhang X, Netchiporouk E, and Ben-Shoshan M
- Subjects
- Adult, Humans, Child, Chronic Disease, Patient Acuity, Quality of Life, Chronic Urticaria diagnosis, Urticaria diagnosis
- Abstract
Background: Few validated tools exist to evaluate chronic urticaria (CU) control in children. Although the Urticaria Control Test (UCT) exhibits favorable clinometric properties in adult CU, it is not yet validated in children., Objective: To evaluate the validity of the UCT for the assessment of pediatric CU., Methods: Children presenting with CU were consecutively recruited and completed both the UCT and the Children's Dermatology Life Quality Index (CDLQI) at study entry. Using the CDLQI as an anchor, we assessed the internal consistency, convergent and known-groups validity, and screening accuracy of the UCT at study entry and at follow-up., Results: A total of 52 children with CU were recruited. The UCT exhibited respectable internal consistency in the evaluation of CU (Cronbach's α, 0.73; 95% CI, 0.62-0.85). UCT and CDLQI scores strongly correlated (r = -0.74; P < .01). The UCT distinguished between different strata of disease severities established by the CDLQI (P < .01). Screening accuracy of the UCT was excellent in the discrimination of poorly controlled CU (area under the curve, 0.82). An optimal cutoff of less than or equal to 10 was determined for defining poorly controlled CU (sensitivity, 95.5%; specificity, 63.3%). Data at follow-up were consistent with data at study entry. Subgroup analyses of patients with chronic spontaneous urticaria were consistent with overall estimates of validity., Conclusions: The UCT is a valid tool for the assessment of pediatric CU and chronic spontaneous urticaria, as evidenced by the acceptable internal consistency, convergent and known-groups validity, and screening accuracy at multiple time points., (Copyright © 2022 American Academy of Allergy, Asthma & Immunology. Published by Elsevier Inc. All rights reserved.)
- Published
- 2022
- Full Text
- View/download PDF
4. Validation of UAS7 among children with chronic spontaneous urticaria.
- Author
-
Gabrielli S, Mulé P, Prosty C, Gooding G, Le M, Zhang L, Netchiporouk E, Baum S, Greenberger S, Ensina LF, Lovett A, Zhang X, and Ben-Shoshan M
- Subjects
- Child, Chronic Disease, Humans, Omalizumab therapeutic use, Treatment Outcome, Anti-Allergic Agents therapeutic use, Chronic Urticaria, Urticaria diagnosis, Urticaria drug therapy
- Published
- 2022
- Full Text
- View/download PDF
5. Cold urticaria in a pediatric cohort: Clinical characteristics, management, and natural history.
- Author
-
Prosty C, Gabrielli S, Mule P, Le Gallee M, Miles LM, Le M, Zhang X, Ensina LF, Netchiporouk E, and Ben-Shoshan M
- Subjects
- Child, Chronic Disease, Cohort Studies, Comorbidity, Female, Humans, Chronic Urticaria, Histamine H1 Antagonists, Non-Sedating, Urticaria diagnosis, Urticaria drug therapy, Urticaria epidemiology
- Abstract
Background: Cold urticaria (coldU) is associated with substantial morbidity and risk of fatality. Data on coldU in children are sparse. We aimed to evaluate the clinical characteristics, management, risk of associated anaphylaxis, and resolution rate of coldU in a pediatric cohort. Additionally, we sought to compare these metrics to children with chronic spontaneous urticaria (CSU)., Methods: We prospectively enrolled children with coldU from 2013-2021 in a cohort study at the Montreal Children's Hospital and an affiliated allergy clinic. Data for comparison with participants with solely CSU were extracted from a previous study. Data on demographics, comorbidities, severity of presentation, management, and laboratory values were collected at study entry. Patients were contacted yearly to assess for resolution., Results: Fifty-two children with cold urticaria were recruited, 51.9% were female and the median age of symptom onset was 9.5 years. Most patients were managed with second-generation H1-antihistamines (sgAHs). Well-controlled disease on sgAHs was negatively associated with concomitant CSU (adjusted odds ratio (aOR) = 0.69 [95%CI: 0.53, 0.92]). Elevated eosinophils were associated with cold-induced anaphylaxis (coldA; aOR = 1.38 [95%CI: 1.04, 1.83]), which occurred in 17.3% of patients. The resolution rate of coldU was 4.8 per 100 patient-years, which was lower than that of CSU (adjusted hazard ratio = 0.43 [95%CI: 0.21, 0.89], p < 10
-2 )., Conclusion: Pediatric coldU bears a substantial risk of anaphylaxis and a low-resolution rate. Absolute eosinophil count and co-existing CSU may be useful predictive factors., (© 2022 EAACI and John Wiley and Sons A/S. Published by John Wiley and Sons Ltd.)- Published
- 2022
- Full Text
- View/download PDF
6. Prevalence, Management, and Anaphylaxis Risk of Cold Urticaria: A Systematic Review and Meta-Analysis.
- Author
-
Prosty C, Gabrielli S, Le M, Ensina LF, Zhang X, Netchiporouk E, and Ben-Shoshan M
- Subjects
- Chronic Disease, Humans, Omalizumab therapeutic use, Prevalence, Anaphylaxis drug therapy, Anaphylaxis epidemiology, Chronic Urticaria, Urticaria drug therapy, Urticaria epidemiology
- Abstract
Background: Cold urticaria is a subtype of chronic inducible urticaria (CIndU) associated with significant morbidity and a risk for anaphylaxis. Few studies have assessed the prevalence, management, and prevalence of associated anaphylaxis of cold urticaria., Objectives: To evaluate the prevalence of cold urticaria among CIndU and chronic urticaria (CU) cases, to assess the management of cold urticaria, and to determine the prevalence of associated anaphylaxis., Methods: We searched PubMed and EMBASE for studies pertaining to cold urticaria and/or CIndU published in the past 10 years. We conducted meta-analyses to evaluate the prevalence of cold urticaria among CIndU and CU cases, the management of cold urticaria with H1-antihistamines and omalizumab, and the prevalence of associated anaphylaxis., Results: Twenty-two studies were included in the systematic review and 14 in the meta-analysis. The pooled prevalence of cold urticaria among patients with CU and CIndU was 7.62% (95% confidence interval [CI], 3.45% to 15.99%; I
2 = 98%) and 26.10% (95% CI, 14.17% to 43.05%; I2 = 97%), respectively. Cold urticaria was managed by H1-antihistamines in 95.67% (95% CI, 92.47% to 97.54%; I2 = 38%) of patients and omalizumab in 5.95% (95% CI , 2.55% to 13.27%; I2 = 83%) of patients. The pooled prevalence of anaphylaxis among patients with cold urticaria was 21.49% (95% CI, 15.79% to 28.54%; I2 = 69%)., Conclusions: Cold urticaria constitutes an appreciable proportion of CIndU and CU cases and is predominantly managed with H1-antihistamines; few patients receive omalizumab. Anaphylaxis is common, and an epinephrine autoinjector prescription may be considered., (Copyright © 2021 American Academy of Allergy, Asthma & Immunology. Published by Elsevier Inc. All rights reserved.)- Published
- 2022
- Full Text
- View/download PDF
7. Increased prevalence of autoimmune diseases in children with chronic spontaneous urticaria.
- Author
-
Le M, Zhang L, Gabrielli S, Prosty C, Miles LM, Netchiporouk E, Baum S, Greenberger S, Ensina LF, Jafarian F, Zhang X, and Ben-Shoshan M
- Subjects
- Child, Chronic Disease, Humans, Prevalence, Autoimmune Diseases epidemiology, Chronic Urticaria, Urticaria epidemiology
- Published
- 2022
- Full Text
- View/download PDF
8. Biomarkers associated with chronic spontaneous urticaria severity in 108 children.
- Author
-
Zhang L, Le M, Gabrielli S, Netchiporouk E, Gooding G, Shand G, Baum S, Greenberger S, Ensina LF, Jafarian F, Zhang X, and Ben-Shoshan M
- Subjects
- Biomarkers, Child, Chronic Disease, Humans, Chronic Urticaria diagnosis, Urticaria diagnosis
- Published
- 2022
- Full Text
- View/download PDF
9. Case of postural urticaria in a 14-year-old girl.
- Author
-
Gabrielli S, Le M, Netchiporouk E, and Ben-Shoshan M
- Subjects
- Adolescent, Chronic Disease, Female, Histamine Antagonists therapeutic use, Humans, Omalizumab therapeutic use, Anti-Allergic Agents therapeutic use, Chronic Urticaria, Urticaria diagnosis, Urticaria drug therapy, Urticaria etiology
- Abstract
Chronic inducible urticaria (CIndU) is a subset of chronic urticaria that has an identifiable trigger. We present a case of postural urticaria induced by change in position in a 14-year-old girl. The patient's CIndU was not adequately managed with both antihistamine and omalizumab treatment, indicating a recalcitrant form of CIndU., Competing Interests: Competing interests: None declared., (© BMJ Publishing Group Limited 2021. No commercial re-use. See rights and permissions. Published by BMJ.)
- Published
- 2021
- Full Text
- View/download PDF
10. Reply to "Comment on: 'Children with chronic urticaria can be effectively controlled with updosing second-generation antihistamines'".
- Author
-
Gabrielli S, Le M, Netchiporouk E, Miedzybrodzki B, Baum S, Greenberger S, Staubach-Renz P, and Ben-Shoshan M
- Subjects
- Child, Chronic Disease, Humans, Chronic Urticaria, Histamine H1 Antagonists, Non-Sedating, Urticaria drug therapy
- Published
- 2020
- Full Text
- View/download PDF
11. Safety of COVID-19 mRNA vaccination and effects of SARS-CoV-2 infection in children and adults with mast cell disorders.
- Author
-
Zhu, Catherine K., Nguyen, Alex, Prosty, Connor, Gabrielli, Sofianne, Mulé, Pasquale, Netchiporouk, Elena, Le, Michelle, Zhang, Xun, Shand, Greg, Baum, Sharon, Hakroush, Reman, Greenberger, Shoshana, Ollech, Ayelet, Miedzybrodzki, Barbara, and Ben-Shoshan, Moshe
- Subjects
MAST cell disease ,URTICARIA ,MAST cells ,COVID-19 vaccines ,VACCINATION complications ,COVID-19 ,SARS-CoV-2 - Abstract
Mastocytosis is characterized by abnormal clonal mast cell proliferation. Given the paucity of data in patients with mastocytosis, it is crucial to assess the safety of COVID-19 vaccines in this population. We aimed to assess the risk of allergic reactions and the effect of COVID-19 infection among patients with mastocytosis. Participants were recruited from Canada and Israel between December 2021 and May 2022. Consenting participants were administered standardized questionnaires querying whether they were infected with COVID-19, if they received the first and second dose vaccines, and post-vaccination side effects including allergic reactions (urticaria/angioedema, current rash flaring, need for updosing medications, or respiratory symptoms) and common side effects including injection site reaction (ISR) and flu-like symptoms. Forty participants with mastocytosis were administered a standardized questionnaire (median age = 9, 59% male). Amongst all participants, 16 (39%) reported COVID-19 infection and most (75%) reported flu-like symptoms, 3 (19%) were asymptomatic, 1 suffered from shortness of breath/chest pain and 1 from facial flushing. Of the 25 participants who were eligible for vaccination (≥ 5 years old), 80% received a first-dose vaccine and 68% received a second-dose vaccine. Of those who received the first-dose vaccine, most (60%) remained asymptomatic, 20% developed flu-like symptoms, 20% had an ISR, and 1 patient had an allergic reaction (urticaria and swelling). Of those who received the second-dose vaccine, most (53%) were asymptomatic, and 1 had an allergic reaction. No significant difference was found between side effects of both vaccine doses. No reactions fulfilled the criteria for anaphylaxis in either dose. This study reveals that among patients with mastocytosis, COVID-19 vaccine and infection were well-tolerated in the majority of cases. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
12. Clinical Characteristics, Management, and Natural History of Chronic Inducible Urticaria in a Pediatric Cohort.
- Author
-
Miles, Laura May, Gabrielli, Sofianne, Le, Michelle, Netchiporouk, Elena, Baum, Sharon, Greenberger, Shoshana, Ensina, Luis F., Jafarian, Fatemeh, Zhang, Xun, and Ben-Shoshan, Moshe
- Subjects
- *
URTICARIA , *NATURAL history , *CHILD patients , *PEDIATRIC clinics , *CHILDREN'S hospitals , *C-reactive protein - Abstract
Background: Some forms of chronic urticaria (CU) can be specifically attributed to a response to a definite trigger, referred to as chronic inducible urticaria (CIndU). We aimed to assess the demographics, clinical characteristics, comorbidities, natural history, and management of pediatric patients with CIndU. Methods: Over a 6-year period, children presenting to the allergy clinic at the Montreal Children's Hospital (MCH) with CIndU were prospectively recruited. CU was defined as the presence of wheals and/or angioedema, occurring for at least 6 weeks. A standardized diagnostic test was used to establish the presence of a specific form of urticaria. Resolution was defined as the absence of hives for 1 year without treatment. Results: Sixty-four patients presented with CIndU, of which 51.6% were male, with a median age of 12.5 (interquartile range 7.3, 15.9) years. Cold CU and cholinergic CU were the most common subtypes (60.3 and 41.3%, respectively). Basophil counts were undetectable in 48.4% of the cases, and C-reactive protein levels were elevated in 7.8% of patients. Of all cases, 71.4% were controlled with second-generation antihistamines. The resolution rate was of 45.3% (95% confidence interval 33.1–57.5%), based on per-protocol population within the 6-year course of the study. Resolution was more likely in patients who presented with well-controlled urticaria control test scores and elevated CD63 counts and in those suffering from thyroid comorbidity. Conclusion: The natural history of CIndU resolution in pediatric patients was relatively low and was associated with elevated CD63 levels, as well as thyroid comorbidity. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.